pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Xarelto
drug
save

Xarelto

Marketedupdated 6mo ago
by Johnson & Johnson Innovative Medicine
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval170 co-mentions · 46 sources
  • tagSmall Molecule85 co-mentions · 46 sources
  • drugRIVAROXABAN85 co-mentions · 46 sources
  • companyLupin Ltd1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Xarelto

  • phase3Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Diseaserecruitingn=7,050
  • phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosisactive not recruitingn=1,683
  • phase1Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulantcompletedn=40
  • N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosisrecruitingn=300
  • —A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)not yet recruitingn=850
  • —An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolismcompletedn=320
  • N/APill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablationrecruitingn=400
  • phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participantsrecruitingn=186

News(3)

  • Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
    Bayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.
    biospace · 6d ago
  • Bayer wins FDA nod for a new kind of blood thinner
    Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
    biopharma_dive · 7d ago
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    biopharma_dive · 4mo ago
brand
Xarelto
generic
rivaroxaban
indication
Atrial Fibrillation
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?